Addition of Mr. Lesley Nernberg brings technical sales and marketing expertise to Asia expansion efforts Termination of distribution agreement with São Paulo-based Look Chemicals creates opportunity for accelerated adoption of OxC-betaTM Livestock in Brazil Ottawa, ON /Business Wire/ July 22, 2021/ Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing …Read More
Media
Recent News
-
22
Jul
2021Avivagen Announces Strategic Changes to Support Growth in Asia and South America
-
11
Jun
2021Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants
Ottawa, ON / Business Wire/ June 11, 2021/ Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, announces that it has received approval by the TSX Venture …Read More
-
08
Jun
2021Avivagen to Present at LD Micro Conference Presentation on June 10th, at 10:30 A.M. EST
Ottawa, ON / Business Wire/ June 8, 2021 / Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, announces that it will be virtually presenting at the …Read More
-
07
Jun
2021Avivagen Inc. Announces Proposed Extension of Warrants and Grant of Options
Ottawa, ON /Business Wire/ June 7, 2021 / Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”),a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announces that it will be requesting approval from the TSX …Read More
-
02
Jun
2021Avivagen Inc. Announces Results for the Second Quarter Ending April 30, 2021
Second Quarter Highlights: • Record 64.5 tonne order for OxC-betaTM Livestock over 18 months • New expansion efforts and customer wins in Central and South America • Launch of first product for human health. Ottawa, ON /Business Wire/ June 2, 2021/ Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing …Read More
Media Coverage
-
Avivagen CEO Interviewed on C-Suite At The Open
Kym Anthony, CEO of Avivagen, was recently interviewed by Karoline Hunter, Head of TSX Company Services at the TMX group.
The interview covered the company story and gives a look ahead at the future of Avivagen’s OxC-BetaTM.
The interview also covers Immune Priming, its powerful anti-inflammatory effect, and its efficacy in improving Gut Health.
-
Copyright © 2021 Avivagen. All Rights Reserved.
